Viread 300 mg 30 tablets — Made in Ireland — Free Delivery

Brand: Gilead
Product Code: Viread
Availability: In Stock

$81.94

Description

Product description

Viread® tablets are used for the indications listed below.

HIV-1 infection

Tablets of the preparation "Viread" for the treatment of HIV-1-infected patients are prescribed in combination with other antiretroviral preparations.

Viread® tablets are prescribed for the treatment of HIV-1-infected adolescents aged 12 to <18 years with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) or toxicity, which excludes the use of first-line preparations.

The choice of Viread® for the treatment of HIV-1-infected patients treated with antiretroviral preparations should be based on individual viral resistance testing data and / or patient treatment history.

Hepatitis B

Viread® is intended for the treatment of chronic hepatitis B in adults with:

compensated liver disease with signs of active viral replication, a constant increase in serum alanine aminotransferase (ALT) levels and a histological manifestation of active inflammation and / or fibrosis;
confirmation of lamivudine-resistant hepatitis B;
decompensated liver disease.

The preparation "Viread®" is intended for the treatment of chronic hepatitis B in adolescents aged 12 to <18 years with: compensated liver disease, signs of active disease of the immune system, that is, active viral replication, a constant increase in the level of alanine aminotransferase (ALT) in blood serum and histological manifestation of active inflammation and / or fibrosis.

Compound

The active ingredient is tenofovir disoproxil fumarate (one coated tablet contains 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil).

Excipients: pregelatinized starch; croscarmellose sodium; lactose monohydrate; microcrystalline cellulose; magnesium stearate; Opadry II White 32K18425 (lactose, monohydrate; hypromellose 2910; titanium dioxide (E 171); triacetin).

Contraindications

hypersensitivity to the active substance or to any of the excipients;

age up to 12 years.

Mode of application

Treatment should be initiated by a physician experienced in the treatment of HIV and / or chronic hepatitis B.

Adults

The recommended dose for HIV treatment or for chronic hepatitis B infection is one tablet taken once daily, taken by mouth with food.

Chronic hepatitis B. The optimal duration of treatment is unknown. Conditions for stopping treatment may be:

treatment of patients with a positive reaction to hepatitis B virus antigen (HBeAg) without cirrhosis should continue for at least 6-12 months after confirmation of HBe seroconversion (disappearance of hepatitis B virus antigens and hepatitis B virus DNA with anti-HBe detection) or HBs seroconversion, or to the disappearance of efficiency; after stopping treatment, the level of ALT and hepatitis B virus DNA in the blood serum should be regularly monitored in order to establish any late relapses of viremia;

Treatment of non-cirrhotic hepatitis B virus antigen-negative patients should continue at least until HBs seroconversion or signs of treatment failure appear; in the case of prolonged treatment, lasting more than 2 years, it is recommended to regularly review the treatment to confirm that the chosen therapy remains appropriate for the patient.

Children

HIV-1. For adolescents aged 12 to <18 years, whose body weight is ≥ 35 kg, the recommended dose of Viread® is one tablet once a day, which is taken orally with food.

Chronic hepatitis B. For adolescents aged 12 to <18 years, whose body weight ≥ 35 kg, the recommended dose of Viread® is one tablet once a day, which is taken orally with food. The optimal duration of treatment is currently unknown.

Way to use

Viread® tablets should be taken orally once a day with food.

If patients have difficulty swallowing, Viread® tablets can be crushed and dissolved in about 100 ml of water, orange or grape juice and consumed immediately.

Application features

Pregnant

The use of tenofovir disoproxil fumarate is possible during pregnancy, if necessary.

Tenofovir has been found to pass into a woman's breast milk. There is insufficient information on the effects of tenofovir on neonates / infants. Therefore, "Viread®" should not be used during breastfeeding. In general, HIV and HBV-infected women are generally advised not to breastfeed to avoid transmitting HIV or HBV to their baby.

There is limited clinical evidence on the effect of tenofovir disoproxil fumarate on fertility. In animal studies, no adverse effects on fertility were found with tenofovir disoproxil fumarate.

Drivers

There have been no studies of the effect on the ability to drive and work with other mechanisms. Patients should be advised that dizziness may occur during treatment with tenofovir disoproxil fumarate.

Overdose

Symptoms: In case of overdose, the patient should be monitored for signs of toxicity, if necessary, standard supportive care should be used.

Treatment: tenofovir can be removed by hemodialysis, the median clearance of tenofovir is 134 ml / minute. The withdrawal of tenofovir by peritoneal dialysis has not been investigated.

Side effects

Adverse reactions in frequency are determined: very often (≥ 1/10), often (from ≥ 1/100 to <1/10).

Disorders of nutrition and metabolism: very often - hypophosphatemia.

From the nervous system: very often - dizziness; often a headache.

From the digestive system: very often - diarrhea, nausea, vomiting; often - abdominal pain, bloating, flatulence.

From the hepatobiliary system: often - an increased level of transaminases.

On the part of the skin and subcutaneous tissue: very often - rashes.

Systemic disorders and disorders associated with the method of administration: very often - asthenia; often tiredness.

Storage conditions

Store at a temperature not exceeding 30 ° C, out of the reach of children.

The shelf life is 5 years.

0 reviews

There are no reviews for this product.